Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Solid Biosciences (SLDB) EBIT Margin (2022 - 2024)

Historic EBIT Margin for Solid Biosciences (SLDB) over the last 3 years, with Q4 2024 value amounting to 53194.67%.

  • Solid Biosciences' EBIT Margin changed N/A to 53194.67% in Q4 2024 from the same period last year, while for Dec 2024 it was 38155.29%, marking a year-over-year decrease of 480033800.0%. This contributed to the annual value of 38155.29% for FY2024, which is N/A changed from last year.
  • As of Q4 2024, Solid Biosciences' EBIT Margin stood at 53194.67%.
  • Solid Biosciences' EBIT Margin's 5-year high stood at 53194.67% during Q4 2024, with a 5-year trough of 411.44% in Q2 2022.
  • Moreover, its 3-year median value for EBIT Margin was 29926.53% (2024), whereas its average is 30335.37%.
  • The largest annual percentage gain for Solid Biosciences' EBIT Margin in the last 5 years was 18047200bps (2024), contrasted with its biggest fall of 18047200bps (2024).
  • Over the past 3 years, Solid Biosciences' EBIT Margin (Quarter) stood at 411.44% in 2022, then soared by 6534bps to 26471.07% in 2023, then skyrocketed by 101bps to 53194.67% in 2024.
  • Its EBIT Margin stands at 53194.67% for Q4 2024, versus 42904.88% for Q3 2024 and 31577.27% for Q2 2024.